John Charles Canning Purchases 4,375 Shares of Femasys (NASDAQ:FEMY) Stock

Femasys Inc. (NASDAQ:FEMY) COO John Charles Canning acquired 4,375 shares of the stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $3.20 per share, with a total value of $14,000.00. Following the completion of the purchase, the chief operating officer owned 4,375 shares of the company’s stock, valued at approximately $14,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Femasys Stock Down 0.8%

Shares of FEMY stock traded down $0.02 during trading hours on Tuesday, reaching $2.35. The company had a trading volume of 228,436 shares, compared to its average volume of 120,035. The company has a market cap of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. Femasys Inc. has a 12 month low of $2.29 and a 12 month high of $22.20. The business has a fifty day simple moving average of $3.87 and a 200-day simple moving average of $7.49.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Friday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $1.43. The business had revenue of $0.42 million during the quarter, compared to the consensus estimate of $0.77 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Femasys to a “hold” rating in a research report on Saturday, June 13th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $80.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of Femasys during the 4th quarter worth $62,000. Banco BTG Pactual S.A. bought a new position in Femasys during the fourth quarter valued at about $88,000. Geode Capital Management LLC increased its holdings in Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after buying an additional 131,052 shares during the last quarter. State Street Corp increased its holdings in Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the last quarter. Finally, Osaic Holdings Inc. bought a new stake in Femasys in the second quarter worth about $45,000. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.